ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
- Posted on August 26, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update STARLIGHT I Dose Expansion Underway Estrella Immunopharma (NASDAQ: ESLA) is currently conducting the Phase 1/2 STARLIGHT-1 trial of EB103 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). The company recently announced that the first patient was dosed in the expansion phase, following encouraging durability data from the Phase 1...
